INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm
Innate Pharma S.A. - American Depositary Shares (IPHA)
Company Research
Source: Business Wire
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or “the Company”) (NASDAQ: IPHA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Innate announced on January 9, 2020, that it would “suspend enrollment of new patients” in the TELLOMAK Phase II trial of lacutamab (IPH4102). The trial was designed to evaluate the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas. The Company’s decision was based on “ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Company’s manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials.” Based on this news, shares of Innate fell by ne
Show less
Read more
Impact Snapshot
Event Time:
IPHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPHA alerts
High impacting Innate Pharma S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IPHA
News
- Innate Pharma: Clarification Regarding SAR443579 DesignationBusiness Wire
- Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.MarketBeat
- Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress [Yahoo! Finance]Yahoo! Finance
- Innate Pharma Highlights Abstracts Selected for EHA 2024 CongressBusiness Wire
- Innate Pharma Reports First Quarter 2024 Business Update and Financial Results [Yahoo! Finance]Yahoo! Finance